Published in Medical Letter on the CDC and FDA, March 17th, 2002
In an analysis of 116 blinded blood samples - 50 from patients with cancer and 66 with nonmalignant disease - the researchers were able to correctly identify all 50 cases of ovarian cancer, including, most significantly, all 18 stage I cases. Of the controls, 63 of the 66 (95%) were identified as noncancer. This is a vast improvement over the currently used ovarian cancer detection technique of identifying the tumor marker CA125...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.